A phase I/II study of 153 Sm EDTMP (Quadramet TM) [samarium 153-SM lexidronam] and PS-341 (Velcade RM) [bortezomib] in patients with relapsed or refractory multiple myeloma

Trial Profile

A phase I/II study of 153 Sm EDTMP (Quadramet TM) [samarium 153-SM lexidronam] and PS-341 (Velcade RM) [bortezomib] in patients with relapsed or refractory multiple myeloma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 May 2011

At a glance

  • Drugs Bortezomib; Samarium-153-SM-lexidronam
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Feb 2009 Phase I results were published in Clinical Cancer Research, according to a EUSAPharma media release.
    • 01 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top